Gyre Therapeutics, Inc. Payments to Acquire Short-term Investments
Gyre Therapeutics, Inc. (GYRE) reported Payments to Acquire Short-term Investments of $564.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2025-11-07
- Gyre Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2020-09-30 was $44.66M, a 47.24% increase year-over-year.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2020-06-30 was $41.06M, a 10.92% increase year-over-year.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2020-03-31 was $6.02M, a 84.80% decline year-over-year.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2019-12-31 was $23.03M, a 63.62% decline year-over-year.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for fiscal 2019 was $129.98M, a 34.66% decline from fiscal 2018.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for fiscal 2018 was $198.91M, a 680.90% increase from fiscal 2017.
- Gyre Therapeutics, Inc. payments to acquire short-term investments for fiscal 2017 was $25.47M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2025-09-30 | $564.00K 10-Q · filed 2025-11-07 | |||
| 2020-09-30 | $44.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $85.72M derived: sum of 2 quarters · filed 2021-11-12 | $91.74M 10-Q · filed 2021-11-12 | $114.77M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $41.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $47.08M 10-Q · filed 2021-08-05 | $70.11M derived: sum of 3 quarters · filed 2021-08-05 | $100.44M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $6.02M 10-Q · filed 2021-05-06 | $29.05M derived: sum of 2 quarters · filed 2021-05-06 | $59.38M derived: sum of 3 quarters · filed 2021-05-06 | $96.40M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $23.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $53.36M derived: sum of 2 quarters · filed 2020-02-20 | $90.38M derived: sum of 3 quarters · filed 2020-08-06 | $129.98M 10-K · filed 2020-02-20 |
| 2019-09-30 | $30.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $67.35M derived: sum of 2 quarters · filed 2020-08-06 | $106.95M 10-Q · filed 2019-11-07 | $170.25M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-06-30 | $37.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $76.62M 10-Q · filed 2020-08-06 | $139.92M derived: sum of 3 quarters · filed 2020-08-06 | $173.20M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $39.60M 10-Q · filed 2020-05-11 | $102.90M derived: sum of 2 quarters · filed 2020-05-11 | $136.18M derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | $63.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $96.58M derived: sum of 2 quarters · filed 2020-02-20 | $198.91M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $33.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $135.61M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $102.33M 10-Q · filed 2019-08-01 | |||
| 2017-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $25.47M 10-K · filed 2019-03-08 | ||
| 2017-09-30 | $16.47M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |